Navigation Links
GlaxoSmithKline Reports Q4 and Year End Results 2008
Date:2/5/2009

LONDON, February 5 /PRNewswire-FirstCall/ -- In a video interview Andrew Witty, GlaxoSmithKline CEO, described the pharmaceutical group's results as "robust" in a year that was "always going to be challenging".

GSK also announced that it will cease providing EPS guidance, to allow a focus on longer term strategic goals.

Describing 2008 as a strategic turning point for GSK Mr Witty said: "We started to make very clear what it would take to really make this company strong over the next few years and how we intend to ensure that we build a business, which can really prosper in a challenging environment."

GSK also announced expanded restructuring savings that the company says will be the catalyst to move from the old business model to the new business model.

The interview is available now on http://w3.cantos.com/glaxosmithkline .

It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives.

If you would like to contact us, please email enquiries@cantos.com or phone +44-207-936-1333.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
10. Vaccinex Antibody Licensed to GlaxoSmithKline
11. Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...A, Va., Nov. 9 CEL-SCI C... Dr. Kenneth S. Rosenthal, Professor of Immunology...s College of Medicine and Pharmacy, reported on wo...he Cleveland Clinic and CEL-SCI on CEL-SCI,s LEAPS...e 7th GTCbio Vaccine: "All Things Considered" Conf...
(Date:11/8/2009)...UNTAIN VIEW, Calif. Nov. 5, 2009 Complete Genomi...pany, today announced publication of a report in t...A sequencing platform, including analysis of seque...nsumables cost for these three genomes sequenced o...nged from $8,005 for 87x coverage to $1,726 for 45...
(Date:11/6/2009)...Y, Mass., Nov. 6 Myriant Technolog...eloper and manufacturer of renewable bio-chemical...echnology provider Uhde GmbH, one of the world,s l...nnounced an alliance for the engineering, procurem... Succinic Acid plants based on renewable feedstock...
(Date:11/6/2009)...RD, Calif., Nov. 6 Intarcia Therap...its ITCA 650 (DUROS® continuous delivery of e...etes at the Ninth Annual Diabetes Technology Meeti...newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,...e Via ITCA 650 Lowers Plasma Glucose, HbA1c and Re...
Breaking Biology Technology:CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 2CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 3Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5
...developments in technology have provided people wi...ayers, and cell phones with digital audio capabili... that may have been considered fantasy 10 years ag...s environment, companies must consider and underst...usiness arrangements with other parties, especiall...
...r,s note: Grady Frenchick co-authored this comment...ectual property associate with Whyte Hirschboeck D...spute over three important University of Wisconsi...lar disputes - shows a strong likelihood that the ... all of its patent rights, even if some of its cla...
... note: Matt Storms is writing a series of articles...nt focuses on the term sheet. , , Most of the ti... are summarized in what is referred to as a term ...s typical for the company to produce the initial t...s will want to negotiate the initial term sheet, e...
Other Biology Technology:Making deals with evolving technologies in mind 2Making deals with evolving technologies in mind 3Making deals with evolving technologies in mind 4Making deals with evolving technologies in mind 5WARF is likely to hold on to stem cell patent rights 2WARF is likely to hold on to stem cell patent rights 3WARF is likely to hold on to stem cell patent rights 4WARF is likely to hold on to stem cell patent rights 5WARF is likely to hold on to stem cell patent rights 6WARF is likely to hold on to stem cell patent rights 7WARF is likely to hold on to stem cell patent rights 8Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5
(Date:11/6/2009)..., DETROIT, Nov. 6 Auburn Hill...LC (LEID) will be installing its locker system and...) (BACS) at the U.S. Department of Health and Huma...sed in Bethesda, MD. The locker system will suppo...le for protecting our nation,s medical research ag...
(Date:11/4/2009)..., PHILADELPHIA Although scientists are reluctant...ntion method, evidence continues to grow about its...udy published in Cancer Prevention Research , a j...arch, which suggests some reduction in oral cancer...or of medicine in the Department of Thoracic/Head ...
(Date:11/4/2009)..., The Singapore laboratory that deciphered the DN...ish) and elephant shark, has joined The Genome 10K...luable repository of DNA sequences on 10,000 speci...n a scale that currently can not be achieved. , ... in a paper published in the Nov. 5, 2009 issue of...
Breaking Biology News(10 mins):Does green tea prevent cancer? Evidence continues to brew, but questions remain 2Singapore scientists join international study of 10,000 vertebrates' genomes 2National Foundation for Infectious Diseases honors VCU physician with Maxwell Finland Award for 2010 53744 1National Foundation for Infectious Diseases honors VCU physician with Maxwell Finland Award for 2010 53744 2National Foundation for Infectious Diseases honors VCU physician with Maxwell Finland Award for 2010 53744 3Smart Choices Program helps shoppers identify food and beverage choices 53741 1Smart Choices Program helps shoppers identify food and beverage choices 53741 2Beautiful plumage 3A Feather color and sex start the species revolution 9485 1
... Parasitic flies introduced to control red importe... central and southeast Texas since the flies, intr... Texas at Austin have discovered using new flytrap...ge Field Laboratory (BFL) have released multiple s...zil and Argentina, to control invasive fire ants w...
... Thanks to the many blood-safety interventions int...sfusion-transmitted infections has become exceedin... England Journal of Medicine, Dr. Morris Blajchman...d medical director, Canadian Blood Services (Hamil...as of Ottawa, puts into perspective the continuing...
... Researchers at Oregon Health & Science Univer...occurring brain substance, can relieve the doldrum...ective disorder, or SAD. The study is publishing o... Academy of Science. , The study was led by Alfred...pioneer in the study of circadian (24-hour) rhythm...
Other Biology News:Fire ant-attacking fly spreading rapidly in Texas 2Fire ant-attacking fly spreading rapidly in Texas 3Blood transfusion-transmitted infections: A global perspective 2Melatonin improves mood in winter depression 2
...tems adds two new Stem Cell Antibody Panels to its...mbryonic Stem Cell Marker Antibody Panel (Catalog ... phosphatase, Nanog, Oct-3/4, SSEA-1 and SSEA-4. T... Plus (Catalog # SC009) contains antibodies agains...
DONKEY SERUM (WITH 0.09% AZIDE) from AbD Serotec
...s Contact Printing Kit contains choice of Printing... Angsroms of Gold over Ti adhesion layer, 1 silico... adhesion layer, or 3 plain glass slides), PDMS St...100 / 200 micron squares or 100 um x 10 mm or 200 ...
Rabbit Anti-Human Melanoma antigen, family C, 1 (MAGEC1) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
Biology Products: